Clinical Trial

Evaluate the Effect of Synbiotics on MAFLD

Study acronym: MAFLD-RCT
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Available data indicates that probiotics may regulate the gut microbiota, while Vitamin E and omega 3 are safe and effective at treating NAFLD patients. In this study, investigators aim to investigate if the enhanced synbiotic preparation of SLP07 is efficacious in liver function improvement in subjects with MAFLD.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-02; most recent amendment 2025-04-01.
Status change: Recruiting → Active, Not Recruiting 2025-03-25
Trial Details
NCT Number NCT06537882
Lead Sponsor GenieBiome Limited
Collaborators: Microbiota I-Centre (MagIC)
Conditions Metabolic Dysfunction-Associated Fatty Liver Disease
Enrollment 54 participants
Start Date 2024-05-17
Primary Completion 2025-02-07 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-03